Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 15/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.40 |
| ▸ | ATF1 | P18846 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | JUN | P05412 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14030761 | 0.85 | EGLN1 (0.39) | CNR2EGLN1 | |
| SCHEMBL14005259 | 0.84 | CNR2 (0.52) | CNR2NFKB1ATF1 | |
| SCHEMBL14005256 | 0.82 | CNR2 (0.55) | CNR2MAPTLMNACYP1A2CYP2C9 | |
| SCHEMBL4745657 | 0.78 | CNR2 (0.76) | CNR2LMNACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL14030749 | 0.69 | ACACB (0.43) | CNR2EGLN1MAPTLMNA | |
| SCHEMBL14005263 | 0.69 | CNR2 (0.58) | CNR2 | |
| SCHEMBL14005260 | 0.69 | CNR2 (0.44) | CNR2 | |
| SCHEMBL14030760 | 0.69 | KMT2A (0.46) | MAPT | |
| SCHEMBL5780255 | 0.66 | CNR2 (0.68) | CNR2NFKB1ATF1CYP1A2CYP2C9 | |
| SCHEMBL5778821 | 0.66 | CNR2 (0.68) | CNR2NFKB1ATF1MAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293711-A1 | Chemokine receptor modulators | METASTATIX, INC. | 2008-11-27 | — | — | US | disclosed |
| WO-2008112156-A1 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293711-A1 | Chemokine receptor modulators | CCR5, CCL2, CXCR4 | CNR2 496/4885NFKB1 526/4885ATF1 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.